Background: Immunodeficiency (ID) correlates with worse outcomes and decreased immune checkpoint molecule expression in melanoma. The impact of ID in mycosis fungoides (MF) is unknown.
Blockade of the programmed cell death 1 (PD1) pathway has proved to be a powerful therapeutic approach for many solid and hematologic malignancies. 1, 2 Clinical trials of PD1 inhibition in patients with cutaneous T-cell lymphomas (CTCLs) 3, 4 are encouraging; however, treatment response is highly variable. New biomarkers to predict response to anti-PD1 therapy are necessary.
In patients with melanoma, the presence of tumor-infiltrating cytotoxic lymphocytes and elevated PD1 and programmed death ligand 1 (PDL1) levels in the tumor microenvironment predict favorable responses to anti-PD1 therapy. 1, 5 This inflamed phenotype is more likely to be identified in patients with immunogenic tumors (eg, those with extensive carcinogenic damage, antigens from oncogenic viruses, and damage due to microsatellite instability). 6, 7 Differences in the underlying immune status of the patient may contribute to differences in tumor-associated immune cell infiltrates. For example, a recent study showed that patients with melanoma with recent pregnancyda state of selective immune tolerancedhad lower levels of tumor-infiltrating lymphocytes, lower PD1 expression in the tumor microenvironment, and worse outcomes than their nonpregnant counterparts. 8 Such findings suggest that cancers arising in the setting of pregnancy and other similarly altered immunologic states could be less susceptible to anti-PD1 therapy.
In this context, we hypothesized that immunodeficiency (ID) is associated with poor outcomes and decreased PD1 and PDL1 expression in patients with mycosis fungoides (MF). We identified patients with MF and a spectrum of unrelated states of immune system dysregulation and compared them with a matched case-control cohort for clinical features, histopathologic characteristics, and expression of PD1 and PDL1. We also compared forkhead box p3 (FOXP3) and interleukin 17 (IL-17) expression, which were previously associated with immune dysregulation and cancer outcomes.
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MATERIALS AND METHODS
A retrospective, case-control study was conducted with the approval of the Memorial Sloan Kettering Cancer Center Institutional Review Board (WA0033-11). A search of the Memorial Sloan Kettering Cancer Center Darwin patient database identified patients with a diagnosis of MF who also carried a diagnosis of chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma, primary ID disorder, pregnancy, or history of immunosuppressive chemotherapy from a prior malignancy (identified by diagnosis code and/or free text search). Diagnoses, as per the International Society for Cutaneous Lymphoma guidelines, 12 were confirmed via review of available clinical, laboratory, and histopathology data. Age-, stage-, and sex-matched patients without immune alteration (1 per test patient) were selected as controls.
Patient charts were reviewed and the following data were collected: age at MF diagnosis; sex; race/ ethnicity; stage at diagnosis and last follow-up; highest lactate dehydrogenase level recorded; types and dates of other malignancies; history of immunotherapy for any condition; history of organ transplantation; history of collagen/vascular, autoimmune, or atopic disease or allergies; and history of infections.
Given the indolent nature of MF, and good-prognosis bias in our younger patient cohort, we reasoned that outcome differences would manifest in treatment failures. Accordingly, history of treatment failure in the follow-up period and treatment failure within 3 years of diagnosis were selected as primary outcomes. Stage progression and all-cause mortality were evaluated as secondary outcomes. A treatment failure was defined as a change in treatment regimen due to unsatisfactory response. Changes in treatment regimen were not considered failure when due to medication intolerance alone.
Hematoxylin and eosinestained slides from tumor specimens were evaluated for the following features: dermal involvement; subcutis involvement; spongiosis; epidermal hyperplasia; ulceration; syringotropism; angiocentrism; interface alteration; cell size (1, 2, or 3 for small, medium, or large), and presence of eosinophils, neutrophils, plasma cells, and histiocytes. Large cell transformation, folliculotropism, and granulomatous disease were assessed via chart review.
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Immunodeficiency is associated with worse outcomes and decreased expression of immune checkpoint molecules in melanoma. 
RESULTS
Characteristics of patients with ID
A total of 23 patients with MF and ID were identified. Of the 23 patients, 7 had recent/ concurrent pregnancy; 1 had HIV; 1 had hypogammaglobulinemia secondary to a protein-losing enteropathy; 1 had idiopathic CD4 cytopenia and hypogammaglobulinemia; 6 had a history of chemotherapy, including R-CHOP ( 
Clinical features of patients with ID and control patients
The matched patients with ID, all patients with ID, and control patients had similar mean ages (49, 47, A subgroup analysis compared patients with lymphocytic malignancy (n = 11) and patients with recent pregnancy (n = 7) with the control patients (Table III and Fig 1) . Patients with a history of lymphocytic malignancy were more likely than the control patients to have treatment failure (63.6% vs 29.4% [P = .046]) and trend toward increased treatment failure within 3 years of MF diagnosis (54.5% vs 23.5% [P = .071]). There were no significant differences between the 2 groups in stage progression or deaths. There was a trend toward increased treatment failure within 3 years of MF diagnosis in patients with recent pregnancy (57.1% vs 23.5% [P = .072]) but no difference in treatment failure overall, stage progression, or death. Tumor histopathology in patients with ID and control patients Samples for histopathologic analysis were available for 12 patients with ID and 10 control patients (Table IV) . Patients with ID were significantly more likely to exhibit angiocentric infiltrates (50% vs 0% [P = .005]) and higher average lymphocyte size (1.92 6 0.51 out of 3 vs 1.30 6 0.48 out of 3 [P = .009]) (Fig 2) . Prevalence of the following features was not significantly different between patients with ID and control patients: large cell transformation, granulomatous infiltrate, folliculotropism, involvement of the dermis, or subcutis, epidermal hyperplasia, ulceration, spongiosis, and syringotropism. Presence of histiocytes, neutrophils, plasma cells, and eosinophils did not differ between ID and control patients.
PD1, PDL1, FOXP3, and IL-17 expression in tumors of patients with ID and control patients
Samples for immunohistochemical analysis were available for 12 patients with ID and 10 control patients. Subgroup analysis was performed for patients with lymphocytic malignancy (n = 6) and patients with recent pregnancy (n = 3) against controls for each marker (Table V and Fig 3) . The percentage of infiltrate staining positive for PD1 was significantly higher in patients with ID (43.3 6 40.2 vs 11.2 6 13.6 [P = .028]) (Fig 4) and patients with lymphocytic malignancy (67.0 6 37.7 vs 11.2 6 13.6 [P = .025]) than in the controls, but there was no difference in patients with recent pregnancy and the controls (12.0 6 9.9 vs 11.2 6 13.6). There were no statistically significant differences between any groups in terms of PDL1, FOXP3, and IL-17 expression. Patients with ID were more likely to have at least 10% of infiltrate labeled for PD1 (81.8% vs 40.0% [P = .031]) and PDL1 (58.3% vs 20.0% [P = .042]) (Fig 5) than the controls were. A level of PD1 positivity of 10% or more was more common in patients with lymphocytic malignancy (100% vs 40% [P = .025]), but not at least 10% PDL1 positivity (50% vs 20% [P = .163]). There were no differences between any groups in terms of 10% or more positivity of FOXP3 or IL-17 staining.
DISCUSSION
MF is the most common CTCL and is characterized by a dysregulated proliferation of mature CD4 1 T cells. Although MF is typically an indolent disease, a subset of MF cases can involve extracutaneous Infiltrates seen in biopsy specimens from control patients with mycosis fungoides were dispersed (A and B), whereas immunodeficient patients showed more angiocentricity (C) and a higher average lymphocyte size (D).
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The effectiveness of immune checkpoint inhibitors in other malignancies makes them an attractive option for advanced-stage MF. High levels of PD1 expression (more than 50% lymphoid infiltrate) have been reported in up to 13% and 89% of cases of MF and Sezary syndrome, respectively. 13 Moderate levels of PD1 expression (more than 30% of lymphoid infiltrate) were reported in up to 40% and 60% of plaque/patch-and tumor-stage MF cases, respectively.
14 These studies suggest that refractory or advanced-stage MF may be sensitive to anti-PD1 therapy. Several PD1/PDL1 blockade therapies are being evaluated in clinical trials for peripheral T-cell lymphomas such as CTCL. Preliminary results from 1 study evaluating nivolumab in patients with relapsed or refractory lymphoma showed that patients with MF and peripheral T-cell lymphoma had overall response rates of 15% and 40%. 3 Initial results from another study evaluating pembrolizumab in patients with refractory MF or Sezary syndrome showed an objective response rate in 38% of treated patients, with another 38% showing disease stability. 15 The positive response in some patients is promising. However, outcome variability complicates treatment decisions. Patients most suited to anti-PD1 therapy seem to be those with an initial immune response to their tumors, which is subsequently quelled by upregulation of immune checkpoint molecules. Even in the absence of immune therapy, patients with MF are more likely to have a favorable clinical course when more CD8 1 cytotoxic T-cells are present in their lesions. 16, 17 We reasoned that this initial immune response may be less likely in patients with underlying immune alteration, and hence, patients with MF and immune alteration may have a worse clinical course and be poor candidates for anti-PD1 therapy.
In our series, patients with MF and ID had rates of stage progression and death similar to those of their immune-intact counterparts. However, patients with ID had more treatment failure than immunocompetent patients. Overall, this is not surprising given the well-established association between various immunodeficienciesdincluding lymphomasdand cancer development and progression. [18] [19] [20] The association between pregnancy and cancer progression specifically is less well established and likely varies by cancer type. For example, there is evidence both for 21 and against 22 an association between pregnancy and poor outcomes in patients with melanoma. In another study, pregnancy was not associated with worse outcome in patients with various types of lymphoma. 23 In our patient cohort, patients with MF and recent pregnancy were nearly twice as likely to have treatment failure, but the result was not significant. Given the short length of followup, chronic nature of MF, and small subgroup sizes, our clinical outcome results should be interpreted with caution. A larger cohort of patients with longer follow-up is needed to confirm the effect of the various immunodeficiencies we examined on outcomes.
Of the histologic features assessed, only angiocentrism and cell size were different between the ID and control groups (Fig 3) . ID cases were more likely to show more than 10% of cells expressing PD1 and/ or PDL1, along with higher expression of PD1. We suggest that the larger cell size in ID cases is due to alterations in cytoskeletal structure and cytoplasmic proteins within the exhausted PD1 1 cells. Moreover, because the PD1 1 cells cluster more around vascular structures (Figs 3 and 4) , the angiocentric pattern seen in ID-associated MF may reflect the increased numbers of PD1 1 cells or their absence in lichenoid infiltrates. Histopathologic features historically associated with worse disease, including depth, ulceration, granulomatous changes, or syringotropism, did not significantly differ between the ID and control groups.
Contrary to our hypothesis, ID was associated with increased PD1 and PDL1 expression. However, analysis of subgroups showed that our results were similar to those of previous studies. Specifically, in our study the association of ID and PD1 expression was most prominent in patients with lymphocytic malignancies, 60% of whom had CLL. Increased PD1 expression in patients with CLL compared with that in healthy patients has been demonstrated in previous studies, 24, 25 and it is reasonable that this increase may persist when patients with CLL develop MF. Additionally, although 1 study of pregnancyassociated melanoma showed decreased PD1 expression compared with that in nonpregnant patients with melanoma, 8 animal studies suggest that the PD1/PDL1 axis plays an important role in fetal tolerance 26, 27 and may be upregulated in pregnancy. In our study, patients with pregnancyassociated MF were more likely to have more than 10% of lymphoid infiltrates express PD1 and PDL1, but this difference was not significant, and the average PD1 and PDL1 expression in these patients was similar to that in the control patients. Larger studies are needed to confirm the effect of pregnancy on PD1/PDL1 expression in patients with MF.
We studied the expression of FOXP3 and IL-17. FOXP3 is often expressed on nonmalignant, tumorinfiltrating regulatory T cells in MF and is associated with improved survival. 11 The survival benefit is thought to be due to downregulation of malignant T cells by regulatory T cells. 28 ID did not significantly alter FOXP3 expression in our study. Although IL-17 has been shown to have both antitumor and protumor activity, 29 a recent systematic review suggested that IL-17 is primarily tumorigenic, with only a subset of IL-17eproducing Th17 cells showing tumor-suppressing effects. 9 The few studies that have examined IL-17 in MF have shown expression in some but not all patients. [30] [31] [32] There was very low or absent IL-17 expression in our study, leaving the role of this cytokine unclear.
Overall, this study suggests that MF arising in the setting of altered underlying immune status may exhibit therapeutically relevant differences in J AM ACAD DERMATOL VOLUME 78, NUMBER 3 pathogenesis from MF arising in patients with unaltered immunity. Specifically, patients with MF and ID may be good candidates for PD1 inhibition. Larger studies stratified by type of ID are needed to clarify these results. 
